ZA986090B - Agents for the prevention and/or treatment of radiation-induced disorders - Google Patents
Agents for the prevention and/or treatment of radiation-induced disordersInfo
- Publication number
- ZA986090B ZA986090B ZA986090A ZA986090A ZA986090B ZA 986090 B ZA986090 B ZA 986090B ZA 986090 A ZA986090 A ZA 986090A ZA 986090 A ZA986090 A ZA 986090A ZA 986090 B ZA986090 B ZA 986090B
- Authority
- ZA
- South Africa
- Prior art keywords
- prevention
- radiation
- treatment
- agents
- induced disorders
- Prior art date
Links
- 208000019095 Radiation-induced disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010094028 Prothrombin Proteins 0.000 abstract 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9188384A JPH1129493A (ja) | 1997-07-14 | 1997-07-14 | 放射線障害予防及び／又は治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA986090B true ZA986090B (en) | 1999-04-20 |
Family
ID=16222690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA986090A ZA986090B (en) | 1997-07-14 | 1998-07-09 | Agents for the prevention and/or treatment of radiation-induced disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5998370A (xx) |
| EP (1) | EP0891778B1 (xx) |
| JP (1) | JPH1129493A (xx) |
| KR (1) | KR100564353B1 (xx) |
| AT (1) | ATE269714T1 (xx) |
| AU (1) | AU732053B2 (xx) |
| CA (1) | CA2242559A1 (xx) |
| DE (1) | DE69824670T2 (xx) |
| DK (1) | DK0891778T3 (xx) |
| ES (1) | ES2219810T3 (xx) |
| ZA (1) | ZA986090B (xx) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531673T2 (de) * | 1994-12-27 | 2004-07-08 | Daiichi Pharmaceutical Co., Ltd. | Tcf mutante |
| JP4006058B2 (ja) | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| CA2253629A1 (en) | 1997-03-14 | 1998-09-24 | Snow Brand Milk Products Co., Ltd. | Agent for preventing and/or treating cachexia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| JP3634359B2 (ja) * | 1992-07-16 | 2005-03-30 | 第一製薬株式会社 | Ｔｃｆ−▲ｉｉ▼を有効成分とする血液凝固正常化剤 |
| DE69314586T2 (de) * | 1992-07-16 | 1998-02-19 | Snow Brand Milk Prod Co Ltd | Arzneimittelzusammensetzung enthaltend TCF-II |
| DE69310525T2 (de) * | 1992-09-16 | 1997-10-02 | Genentech Inc | Schutz gegen leberschäden mit hgf |
| NZ298141A (en) * | 1994-12-27 | 2000-12-22 | Snow Brand Milk Products Co Ltd | Treating lipid metabolism disorder using TCF-II |
| JP4006058B2 (ja) * | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| CA2253629A1 (en) * | 1997-03-14 | 1998-09-24 | Snow Brand Milk Products Co., Ltd. | Agent for preventing and/or treating cachexia |
-
1997
- 1997-07-14 JP JP9188384A patent/JPH1129493A/ja active Pending
-
1998
- 1998-07-06 AU AU74174/98A patent/AU732053B2/en not_active Ceased
- 1998-07-07 CA CA002242559A patent/CA2242559A1/en not_active Abandoned
- 1998-07-08 KR KR1019980027414A patent/KR100564353B1/ko not_active IP Right Cessation
- 1998-07-09 EP EP98112761A patent/EP0891778B1/en not_active Expired - Lifetime
- 1998-07-09 ES ES98112761T patent/ES2219810T3/es not_active Expired - Lifetime
- 1998-07-09 ZA ZA986090A patent/ZA986090B/xx unknown
- 1998-07-09 DE DE69824670T patent/DE69824670T2/de not_active Expired - Fee Related
- 1998-07-09 DK DK98112761T patent/DK0891778T3/da active
- 1998-07-09 AT AT98112761T patent/ATE269714T1/de not_active IP Right Cessation
- 1998-07-14 US US09/115,294 patent/US5998370A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0891778A2 (en) | 1999-01-20 |
| ES2219810T3 (es) | 2004-12-01 |
| AU7417498A (en) | 1999-01-21 |
| DK0891778T3 (da) | 2004-08-09 |
| KR19990013676A (ko) | 1999-02-25 |
| EP0891778B1 (en) | 2004-06-23 |
| DE69824670T2 (de) | 2004-12-09 |
| KR100564353B1 (ko) | 2006-09-18 |
| DE69824670D1 (de) | 2004-07-29 |
| JPH1129493A (ja) | 1999-02-02 |
| AU732053B2 (en) | 2001-04-12 |
| ATE269714T1 (de) | 2004-07-15 |
| EP0891778A3 (en) | 2000-01-26 |
| US5998370A (en) | 1999-12-07 |
| CA2242559A1 (en) | 1999-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9707570A (es) | Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria. | |
| HK1046274A1 (en) | Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders. | |
| IL143921A0 (en) | Compositions for the treatment and prevention of tumors and tumor-related disorders | |
| HK1032759A1 (en) | Apparatus for restoring the balance of the human body. | |
| NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| HK1020259A1 (en) | Composition for use in the treatment and prevention of hyperuricemia. | |
| ZA9811507B (en) | Combination effective for the treatment of impotence. | |
| ZA965938B (en) | Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system. | |
| NZ513650A (en) | Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo | |
| ZA973622B (en) | Use of forms of hyaluronic acid (HA) for the treatment of cancer. | |
| AU3745795A (en) | Use of CCK-B receptor antagonists for the treatment of sleepdisorders | |
| IL127739A0 (en) | Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases | |
| HUP0003097A3 (en) | Use of intravenous contrast agents and devices for projection mammography | |
| ZA97252B (en) | Compositions for the prevention and treatment of osteoporosis. | |
| ZA962715B (en) | Pharmaceutical agents for the treatment of Alzheimer's disease. | |
| EP0592903A3 (en) | Use of Ancrod in the manufacture of medications for the treatment of restenosis. | |
| AU7105498A (en) | Combination therapy for the prevention and treatment of osteoporosis | |
| AP9200355A0 (en) | "Therapeutic agent" | |
| ZA986090B (en) | Agents for the prevention and/or treatment of radiation-induced disorders | |
| ZA935154B (en) | Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions | |
| EP0981357A4 (en) | METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | |
| AU5558498A (en) | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis | |
| BG101145A (en) | USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA | |
| IL120005A (en) | Pharmaceutical compositions for the treatment of the eye | |
| EP0733365A3 (en) | Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer |